Introduction
Resiliva is identified on this website as a product containing resmetirom in stated strengths of 80 mg and 100 mg. Resmetirom is an oral prescription medicine belonging to the selective thyroid hormone receptor-beta agonist class.
Its established therapeutic role concerns certain adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), previously called nonalcoholic steatohepatitis (NASH), and moderate to advanced liver fibrosis.
Understanding the medicine involves more than knowing its name or strength. Patients should understand its intended treatment population, how it works, potential adverse reactions, interactions, monitoring requirements and the need for professional medical supervision.
The exact manufacturer, formulation and regulatory status of Resiliva have not been independently confirmed from the information available for this website. Product-specific details should therefore be verified separately from information about the established reference product REZDIFFRA.
What Is Resmetirom?
Resmetirom is a selective agonist of thyroid hormone receptor-beta, commonly abbreviated as THR-β. This receptor participates in metabolic regulation in the liver, including processes involved in lipid handling.
The medicine was developed to influence metabolic pathways relevant to excess liver fat and MASH. In clinical studies of the reference product, treatment improved certain measures of MASH and liver fibrosis in a proportion of eligible patients.
Resmetirom is a prescription medicine, and its use requires appropriate clinical assessment. It is not a general treatment for all liver diseases or a replacement for comprehensive medical care.
Understanding MASH and Liver Fibrosis
MASH is a metabolic liver disease characterized by fat accumulation, inflammation and liver-cell injury.
Ongoing liver injury can lead to fibrosis, which involves the accumulation of scar tissue. Fibrosis can progress over time and, in some patients, eventually result in cirrhosis.
The established U.S. indication for REZDIFFRA concerns a defined group of adults with noncirrhotic MASH and moderate to advanced fibrosis, generally stages F2 and F3.
Not everyone with fatty liver has MASH, and not everyone with MASH meets the criteria for resmetirom. A qualified healthcare professional must assess the diagnosis and fibrosis stage using appropriate clinical information.
How the Medicine Works
Resmetirom selectively activates THR-β in the liver. This influences metabolic pathways involved in lipid regulation and can reduce liver fat.
The medicine’s mechanism is designed to address aspects of metabolic liver disease. It does not guarantee that inflammation will resolve or that all existing fibrosis will reverse.
Treatment response varies between individuals. Clinical follow-up is needed to assess the patient’s condition and determine whether the overall treatment plan remains appropriate.
Stated Strengths: 80 mg and 100 mg
The strengths specified for Resiliva on this website are 80 mg and 100 mg. These figures describe the stated amount of active ingredient per dosage unit, assuming the product documentation confirms those strengths.
The reference product REZDIFFRA is supplied in 60 mg, 80 mg and 100 mg tablet strengths in U.S. labeling. A matching strength does not prove that two products have identical formulations or regulatory status.
Patients should use only the strength and dose prescribed by their healthcare professional. They should not combine dosage units or change the regimen independently.
General Administration Principles
The U.S. reference-product labeling recommends once-daily administration, with the dose based on actual body weight.
The labeled U.S. REZDIFFRA regimen is 80 mg once daily for adults weighing less than 100 kg and 100 mg once daily for adults weighing 100 kg or more.
These are reference-product instructions, not a personalized prescription or confirmation of Resiliva’s authorized dosing. The applicable product information and professional instructions should always take priority.
Potential Adverse Reactions
Reported adverse reactions associated with resmetirom include diarrhea, nausea, itching, vomiting, constipation, abdominal discomfort and dizziness.
The U.S. reference-product labeling also includes a warning concerning hepatotoxicity and precautions regarding gallbladder-related adverse reactions.
Patients should discuss persistent or worsening symptoms with their healthcare professional. Symptoms such as jaundice, dark urine, persistent unusual fatigue or severe abdominal pain warrant prompt medical assessment.
Drug Interactions
Resmetirom can interact with certain medicines, including some statins and medicines that affect CYP2C8.
Statins are commonly used to manage cholesterol. Because resmetirom can increase exposure to certain statins, the healthcare professional may need to review the exact medicine and dose.
Patients should provide a complete list of prescription medicines, nonprescription products, vitamins and herbal supplements. They should not stop or adjust existing treatment without professional guidance.
Lifestyle and Comprehensive Care
Resmetirom is used alongside diet and exercise under the established reference-product indication.
A comprehensive plan may also address blood glucose, cholesterol, body weight, blood pressure and other metabolic risk factors. The appropriate approach should be individualized to the patient’s medical history and abilities.
Lifestyle measures support overall health but should not be presented as a guaranteed cure for MASH or fibrosis.
Product Verification
Before using a product identified as Resiliva, check its exact name, active ingredient, strength, dosage form, manufacturer, batch number, expiry date and applicable registration details.
If information is missing or inconsistent, consult a licensed pharmacist or relevant medicines regulatory authority. The existence of an established reference product does not authenticate another brand.
Medical Disclaimer
This page provides general educational information and does not replace professional medical advice or official prescribing information.
The established reference-product indication and dosing instructions should not be treated as proof that Resiliva is authorized for the same use or regimen. Treatment decisions require professional assessment and verification of the exact product.
References
- U.S. Food and Drug Administration: REZDIFFRA prescribing information.
- DailyMed: Current reference-product labeling.
- European Medicines Agency: REZDIFFRA product information.
- Madrigal Pharmaceuticals: Official reference-product information.